Skip to main content

Endo International, OPANA ER is in the News, Vasostrict is Also in Investor's Focus

NEW YORK, NY / ACCESSWIRE / January 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Endo International plc (NASDAQ: ENDP), a provider of generic and specialty branded pharmaceuticals. The company's primary focus is the U.S. market, although it does have international operations. With respect the U.S. generic drugs, Endo first-to-market opportunities and high-barrier-to-entry products that are difficult to manufacture, or that face complex legal and regulatory challenges.

Endo's current research and development pipeline has more than 200 products in various stages of development, including 120 pending abbreviated new drug applications (ANDAs) representing approximately $32 billion of annual sales for the corresponding branded drug products.

Get more details on the status of OPANA ER and Vasostrict and an analysts review READ MORE

Copy and paste to your browser may be required to view the report - http://bit.ly/2mGTiRH-ENDO

On July 6, 2017, Endo complied with an FDA request to voluntarily withdraw OPANA ER from the market. This request was prompted by a review of available post marketing data which indicated that the benefits of the drug may no longer outweigh its risks.

Endo's other generic products consist of sterile injectables that are generally difficult to manufacture, and new launches and alternative dosages (i.e. liquids, semi-solids, patches, powders, ophthalmics, and sprays). The company's most significant product from these categories is Vasostrict, the first and only vasopressin injection product approved by the FDA. Vasostrict accounts for approximately 13 percent of revenue.

Read about the ENDP market, and development pipeline, and a Q3 financial review READ MORE

Copy and paste to your browser may be required to view the report - http://bit.ly/2mGTiRH-ENDO

Disclosure

Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES

The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Nielson, a CFA® charter holder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT:

editor@tradersnewssource.com

SOURCE: Traders News Source

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.